Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

2.4K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.4K
Epilepsy ll: Types01:22

Epilepsy ll: Types

24
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
24
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Seizures ll: Types01:19

Seizures ll: Types

23
Seizures are sudden bursts of abnormal electrical discharge in the brain that interfere with normal function. They are commonly divided into three groups: focal seizures, generalized seizures, and other types that do not fit neatly into either category.Focal SeizuresFocal seizures begin in a single brain region. When awareness is preserved, they are called focal aware seizures and may cause sensations such as tingling, unusual smells, or flashing lights. When awareness is impaired, they are...
23
Seizures l: Introduction01:20

Seizures l: Introduction

30
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
30
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuropsychological functioning and progression in Lafora disease.

Epilepsia·2026
Same author

FRRS1L gene replacement ameliorates disease phenotypes in the mouse model of developmental and epileptic encephalopathy 37.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Lafora disease gene therapy: EPM2A but not EPM2B overexpression results in Lafora body formation.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Neurofilament Light Chain as a Biomarker of Disease Progression in Lafora Disease.

Neurology. Genetics·2025
Same author

The 9th annual Lafora science symposium: a rare epilepsy community makes progress towards clinical readiness.

Epilepsy & behavior : E&B·2025
Same author

Autosomal Recessive Cerebellar Ataxias: Translating Genes to Therapies.

Annals of neurology·2025

Related Experiment Video

Updated: Apr 24, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.5K

The progressive myoclonus epilepsies.

Berge A Minassian1

  • 1Division of Neurology, Department of Paediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada; Program in Genetics and Genome Biology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada; Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada.

Progress in Brain Research
|September 8, 2014
PubMed
Summary
This summary is machine-generated.

Progressive myoclonus epilepsies (PME) are severe neurodegenerative disorders often starting in childhood. Understanding their genetics, particularly neuronal ceroid lipofuscinoses (NCL), offers hope for new treatments for these intractable epilepsies.

Keywords:
BattenGOSR2GaucherKufLaforaUnverrichtmitochondrialsialidosis

More Related Videos

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

1.8K
Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

22.8K

Related Experiment Videos

Last Updated: Apr 24, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.5K
Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

1.8K
Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

22.8K

Area of Science:

  • Neurogenetics
  • Epilepsy research
  • Lysosomal storage diseases

Background:

  • Progressive myoclonus epilepsies (PME) are a group of severe neurodegenerative disorders characterized by myoclonus and epilepsy.
  • These conditions predominantly affect children and are often fatal.
  • This review focuses on PME with multiple familial cases, highlighting neuronal ceroid lipofuscinoses (NCL) as the largest subgroup.

Purpose of the Study:

  • To review the genetics of PME, using NCL as a representative model.
  • To explore the relationship between neurodegeneration and epileptogenesis in PME.
  • To identify potential therapeutic avenues for PME, given their genetic basis and metabolic nature.

Main Methods:

  • Review of existing literature on PME genetics, focusing on monogenic, autosomal recessive inheritance patterns.
  • Analysis of gene functions, particularly those encoding lysosomal proteins.
  • Examination of the clinical presentation and progression of PME to understand disease mechanisms.

Main Results:

  • Most PME are monogenic, autosomal recessive inherited disorders.
  • A significant proportion of PME genes encode lysosomal proteins.
  • Understanding the genetic underpinnings of PME, especially NCL, is crucial for addressing the "why PME?" question.

Conclusions:

  • The genetic knowledge of PME, particularly NCL, is advanced, offering a strong foundation for research.
  • PME, despite their severity, often originate from simple metabolic defects, suggesting potential for therapeutic intervention.
  • This group of intractable epilepsies holds significant promise for the development of future treatments and cures.